1 rich Libsyn https://www.libsyn.com 300 600 🫀 AF + just one stroke-risk factor: anticoagulate or not? The SINGLE-AF randomized trial tackled this common clinical gray zone. At 24 months, the composite of stroke, systemic embolism, major bleeding, or cardiovascular death occurred in 0.5% with a DOAC vs 1.5% without anticoagulation (HR 0.31; P=0.03). 🎯 ⚠️ Only 17 primary events occurred, so the effect estimate remains imprecise. Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk.pdf 💡 Takeaway: SINGLE-AF strengthens the case for DOAC therapy in selected intermediate-risk AF patients—but individualized decision-making remains essential. Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity! http://www.MasterMedFacts.com <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/42597785/height/300/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="300" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/205565020